This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe atopic dermatitis.
Although atopic dermatitis in infancy was not associated with later behavioral problems, at 6.5 years old, children who experienced asthma or atopic dermatitis symptoms within the past year were at increased risk for concomitant emotional problems.
Children with both atopic dermatitis and food allergy have stratum corneum abnormalities that distinguish them from other atopic dermatitis endotypes and children without atopic disease.
Children with atopic dermatitis were more likely to report worse sleep quality, with increased odds of experiencing more sleep-quality disturbances.
The FDA has approved Dupixant to treat moderate-to-severe atopic dermatitis in adolescent patients.
Gestational duration and Cesarean sections were associated with comorbid atopic dermatitis and food allergies in children, respectively.
In a phase 2b trial, success rates were higher with TRPV1 antagonist than with vehicle cream.
The prevalence of depression in patients with atopic dermatitis was higher than in those without atopic dermatitis.
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.
